Work

Phase I Dose-Escalation Study of CAT-8015 (HA22), A CD22-Specific Targeted Immunotoxin, in Relapsed or Refractory Hairy Cell Leukemia.

Year: 2009

Type: article

Source: Blood

DOI: 10.1182/blood.v114.22.888.888

Authors: Robert J Kreitman, Martin S. Tallman, Steven Coutre, Tadeusz Robak, Wyndham H Wilson, Maryalice Stetler-Stevenson, Pierre Noel, David J. FitzGerald, Manuela Buzoianu, Robert Lechleider, Karen Kaucic, Ira Pastan

Institutions: National Institutes of Health, National Cancer Institute, Center for Cancer Research, Northwestern University, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Stanford Medicine, Stanford University, Medical University of Lodz, National Institutes of Health Clinical Center

Language: English

Topic: Chronic Lymphocytic Leukemia Research

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2979463318

FWCI: 1.158

Cites:

Cited by: 9

Related to: 10